SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results